Chronic Lymphocytic Leukemia | Specialty

Fixed-Duration Therapy for Relapsed CLL

January 28th 2020

Health Maintenance in CLL

January 28th 2020

Distinguishing Features Among BTK Inhibitors

January 28th 2020

Combining Targeted Therapies in CLL

January 28th 2020

Ibrutinib + Venetoclax for CLL

January 28th 2020

Treatment for Younger Fit Patients With CLL

January 28th 2020

The Role of Venetoclax + Rituximab in CLL

January 28th 2020

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

January 28th 2020

Long-Term Experience With BTK Inhibitors for CLL

January 28th 2020

Chemoimmunotherapy for CLL; Still a Role?

January 28th 2020

Mutation Status Throughout the CLL Clinical Course

January 28th 2020

Prognostic Factors in Patients With CLL

January 28th 2020

Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLL

January 24th 2020

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

Dr. Sharman on the Design of the ELEVATE-TN Trial in CLL

January 22nd 2020

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

Advances Continue at Rapid Pace in CLL Paradigm

January 21st 2020

Bita Fakhri, MD, discusses data from several recent trials in chronic lymphocytic leukemia and focused on other regimens moving through the pipeline.

Dr. Pagel on the ELEVATE-TN Trial in CLL

January 21st 2020

John M. Pagel, MD, PhD, discusses the phase III ELEVATE-TN trial in chronic lymphocytic leukemia.

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

January 16th 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

January 14th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Long-Term Follow-Up of Acalabrutinib in Patients With MCL and CLL

January 10th 2020

Kellie Ryan, MPH, discusses the importance of long-term follow-up with acalabrutinib in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

Dr. Fakhri on Selecting the Optimal Treatment in CLL

January 10th 2020

Bita Fakhri, MD, MPH, discusses considerations in selecting the optimal treatment in chronic lymphocytic leukemia.